package_of_lutera_birth_control_pills

Actavis contraceptives recalled after packaging errors

pharmafile | July 9, 2015 | News story | Manufacturing and Production |  Actavis, FDA, manufacturing, packaging, product recall, production, recalls 

Actavis is voluntarily recalling more than half a million boxes of contraceptive pills in the United States due to problems with the packaging of the medicines.

According to the FDA Enforcement Report, Actavis is recalling 26 lots, amounting to 511,283 boxes of their Lutera (levonorgestrel/ethinyl estradiol) contraceptive pills after learning they were distributed with out-dated package inserts. The pills were manufactured for Actavis by contract manufacturer Patheon.

The Class III recall indicates that there is no danger to consumers and comes after two other recalls of birth control pills this year in Canada.

In April Johnson & Johnson recalled a single batch of Ortho-Cept (desogestrel ethinyl/estradiol) tablets due to the potential that the potency of the two active ingredients may not meet specifications, according to Health Canada. As a result, the regulator pointed out that contraceptive might not be effective, and that women were at risk of unwanted pregnancies.

Advertisement

In 2012, Pfizer recalled a million packages of its Lo/Ovral-28 (ethinyl estradiol and norgestrel) pills after the packages were found to have either too many pills with active ingredient or too few. It followed a warning issue from Health Canada who stated the expired pills might not meet specifications and could result in unwanted pregnancies.

Yasmita Kumar

Related Content

Johnson & Johnson submits robotic surgical system for De Novo classification

Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …

MedPharm announces US FDA inspection of North Carolina manufacturing facility

MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

The Gateway to Local Adoption Series

Latest content